Olvimulogene nanivacirepvec
- Generic Name
- Olvimulogene nanivacirepvec
- Brand Names
- -
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 1473430-36-2
- Unique Ingredient Identifier
- CF19SF72O5
- Background
Olvimulogene nanivacirepvec is under investigation in clinical trial NCT01443260 (A Study of GL-ONC1, an Oncolytic Vaccinia Virus, in Patients With Advanced Peritoneal Carcinomatosis).
- Associated Conditions
- -
- Associated Therapies
- -
Efficacy & Safety of Olvimulogene Nanivacirepvec & Platinum-doublet + Physician's Choice of Immune Checkpoint Inhibitor Compared to Docetaxel in NSCL Cancer
- Conditions
- Advanced Non-squamous Non-small-cell Lung CancerAdvanced Squamous Non-Small Cell Lung CarcinomaNon-small Cell Lung Cancer RecurrentMetastatic Non-squamous Non Small Cell Lung CancerMetastatic Squamous Non-Small Cell Lung CarcinomaNon-small Cell Lung CancerNon-small Cell Lung Cancer Stage IVNon-small Cell Lung Cancer Stage III
- Interventions
- First Posted Date
- 2024-06-18
- Last Posted Date
- 2024-12-02
- Lead Sponsor
- Genelux Corporation
- Target Recruit Count
- 142
- Registration Number
- NCT06463665
- Locations
- 🇺🇸
Michigan Hematology and Oncology Consultants, Dearborn, Michigan, United States
🇺🇸Oakland Medical Group, Farmington Hills, Michigan, United States
🇺🇸Texas Oncology - Austin Central, Austin, Texas, United States
Efficacy & Safety of Olvi-Vec and Platinum-doublet + Bevacizumab Compared to Physician's Choice of Chemotherapy and Bevacizumab in Platinum-Resistant/Refractory Ovarian Cancer (PRROC) (OnPrime, GOG-3076)
- Conditions
- Interventions
- First Posted Date
- 2022-03-16
- Last Posted Date
- 2024-12-02
- Lead Sponsor
- Genelux Corporation
- Target Recruit Count
- 186
- Registration Number
- NCT05281471
- Locations
- 🇺🇸
Sarasota Memorial Research Institute, Sarasota, Florida, United States
🇺🇸University of Texas Science Center at Houston, McGovern Medical School, Houston, Texas, United States
🇺🇸The University of South Alabama, Mitchell Cancer Institute, Mobile, Alabama, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.